Benefits
Indigestion symptom scores in a 30-day placebo-controlled trial
In 48 randomized adults with moderate to severe functional dyspepsia (43 finished), 250 mg of Asafin twice daily (about 180 mg of asafoetida gum a day) lowered three digestive symptom scores more than placebo over 30 days, and 66% of the Asafin group were symptom-free at the end. The maker funded the trial, and 3 of its 5 authors were from the company.
Bloating, early fullness and belching in a 14-day placebo-controlled trial
In 62 adults with indigestion symptoms (56 finished), one 250 mg capsule a day (a second allowed on symptom days) for 14 days reduced bloating, early satiety and belching more than placebo over time. Heartburn was lower overall, but its change over time, like that of after-meal fullness, upper stomach pain and burning, and nausea, did not differ significantly from placebo. The maker funded the trial.
Stool form and gut bacteria in a 14-day trial
In the same 14-day trial, hard stool types (Bristol types 1 and 2) fell from 100% of the Asafin group at baseline to 25% by day 14, while shifts on placebo were not significant. The Firmicutes-to-Bacteroidetes ratio of gut bacteria fell by about 72% on Asafin, and the placebo group's bacteria did not change significantly. How these shifts relate to symptoms was not tested.
Sleep questionnaire and reaction time scores in a 14-day trial
In the same 14-day trial, Bergen Insomnia Scale scores improved about 10 points more than on placebo, and choice reaction time fell 44% on Asafin with no change on placebo. Both were secondary outcomes in people with indigestion symptoms. The authors credit gut-brain signaling, which the study did not test.
Mechanism of action
Gut microbiome shifts
In the 14-day trial, Asafin lowered the Firmicutes-to-Bacteroidetes ratio, increased Bacteroides and Prevotella, and reduced some Escherichia, Clostridia and Ruminococcus taxa. The authors suggest the fenugreek fiber carrier and asafoetida compounds may act as prebiotics, but the fiber was never tested alone, so its share of any effect is unknown.
Proposed gut-brain link
The 14-day trial's authors propose that microbiome changes explain the reaction-time and sleep findings through gut-brain signaling. The study measured both but did not test whether one caused the other, so this remains a hypothesis from a single small trial.
Gut hormone markers in a rat model (animal study)
The 14-day trial report summarizes a maker-linked rat study in which asafoetida improved gut lining integrity and balanced gut-brain hormones and signaling chemicals such as ghrelin, leptin and serotonin after cisplatin-induced stomach upset. These are animal data; gut hormones and gastric emptying have not been measured in people taking Asafin.
FenuMat fiber encapsulation
Asafin is made by dispersing asafoetida oleo-gum resin onto fenugreek soluble fiber (galactomannans) in a water-based process, giving a free-flowing powder with reduced taste and odor. Laboratory dissolution tests showed sustained release; human absorption has not been studied in the papers cited here.
Gut muscle relaxation and stomach lining effects (lab and animal studies)
In isolated guinea-pig intestine, an asafoetida gum extract cut spontaneous contractions to about half of control and relaxed muscle contracted by acetylcholine, histamine or potassium. In rats, Asafin at 250 mg/kg reduced ethanol-induced stomach ulcers, and it reduced paw swelling in mice. These effects have not been tested in people.
Clinical trials
Randomized, double-blind, placebo-controlled trial at one hospital in Bangalore, India, in adults with moderate to severe functional dyspepsia: hard-shell capsules of Asafin, asafoetida resin bound to fenugreek fiber (250 mg with about 90 mg asafoetida gum), twice daily, or placebo (microcrystalline cellulose with a trace of asafoetida for smell) for 30 days. Funded by the maker, Akay; 3 of the 5 authors were from the company. Retrospectively registered (CTRI/2018/01/011149): the registry lists a first enrollment date of December 2015 and registration in January 2018. The abstract calls the 43 analyzed participants randomized, but the paper's flow diagram shows 48 randomized. (Mala et al. 2018, Evid Based Complement Alternat Med)
60 adults aged 25 to 55 with functional dyspepsia by Rome III criteria were enrolled from outpatients; 12 declined at the first visit, 48 were randomized (24 per group), and 5 dropped out or broke protocol (3 Asafin, 2 placebo), leaving 43 analyzed (21 Asafin, 22 placebo). Reflux disease and peptic ulcer were exclusions.
Overall scores on three questionnaires (GSRS, GDSS and NDI) fell significantly more than on placebo (p of 0.001 or less); GSRS fell from about 44 to 19 on Asafin versus 45 to 39 on placebo. About 81% of the Asafin group improved on all three and 66% were symptom-free at 30 days. 87% of the Asafin group reported using no synthetic drugs during the study, while 61% of placebo users reported repeated use. No adverse events; blood counts did not change, and liver and kidney markers stayed within normal ranges. Small and single site.
Randomized, double-blind, placebo-controlled trial of Asafin (asafoetida resin in a fenugreek-fiber hydrogel), one 250 mg capsule before breakfast for 14 days, with a second allowed on days with symptoms (maximum 2 a day); placebo was flavored microcrystalline cellulose. The asafoetida content per capsule was not reported. Funded by the maker, Akay Natural Ingredients; 3 of the 7 authors were associated with the company. Registered CTRI/2022/07/044075; the registry entry describes three arms (products coded ASFP001/21 and SMXP001/22, and placebo), two 250 mg capsules a day and a target of 93, while the paper reports two arms (Asafin and placebo) and one capsule a day with a second allowed. (Das et al. 2025, Medicine (Baltimore))
62 adults aged 18 to 75 with mild to moderate functional dyspepsia symptoms by Rome IV criteria; 56 finished (2 Asafin and 4 placebo dropouts).
Early satiety, bloating and belching fell more over time than on placebo (treatment by time p = 0.024, 0.004 and 0.042; belching treatment p = 0.030). Heartburn was lower on Asafin overall (treatment p = 0.006), but its treatment by time result was not significant (p = 0.161), although the abstract reports otherwise; in separate day-14 rank tests, early satiety, after-meal fullness, bloating, belching and heartburn scores were each lower than on placebo (p of 0.015 or less). After-meal fullness was lower overall (treatment p = 0.004) but not over time (treatment by time p = 0.181), and upper stomach pain, upper stomach burning and nausea showed no significant treatment by time effect. 8 Asafin and 14 placebo users sometimes took 2 capsules a day, and about 11 placebo users took acid-reducing drugs. Secondary outcomes: sleep scores and reaction time improved; no safety issues in blood tests, and 7 people noticed the taste.